Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

Cited In for PubMed (Select 11822930)

1.

Birth defects in a cohort of infants born to HIV-infected women in Spain, 2000-2009.

Prieto LM, González-Tomé MI, Muñoz E, Fernández-Ibieta M, Soto B, Álvarez A, Navarro ML, Roa MÁ, Beceiro J, de José MI, Olabarrieta I, Lora D, Ramos JT; Madrid Cohort of HIV-Infected Mother-Infant Pairs.

BMC Infect Dis. 2014 Dec 24;14:700. doi: 10.1186/s12879-014-0700-3.

2.

Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants.

Williams PL, Crain MJ, Yildirim C, Hazra R, Van Dyke RB, Rich K, Read JS, Stuard E, Rathore M, Mendez HA, Watts DH; Pediatric HIV/AIDS Cohort Study.

JAMA Pediatr. 2015 Jan;169(1):48-55. doi: 10.1001/jamapediatrics.2014.1889.

PMID:
25383770
3.

Tuberculosis and the obstetrician-gynecologist: a global perspective.

Molina RL, Diouf K, Nour NM.

Rev Obstet Gynecol. 2013;6(3-4):174-81.

4.

First trimester exposure to antiretroviral therapy and risk of birth defects.

Phiri K, Hernandez-Diaz S, Dugan KB, Williams PL, Dudley JA, Jules A, Callahan ST, Seage GR 3rd, Cooper WO.

Pediatr Infect Dis J. 2014 Jul;33(7):741-6. doi: 10.1097/INF.0000000000000251.

PMID:
24445829
5.

Antiretroviral therapy, pregnancy, and birth defects: a discussion on the updated data.

Prestes-Carneiro LE.

HIV AIDS (Auckl). 2013 Aug 1;5:181-9. doi: 10.2147/HIV.S15542. eCollection 2013.

6.

Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.

Thorsteinsson K, Ladelund S, Jensen-Fangel S, Johansen IS, Katzenstein TL, Pedersen G, Storgaard M, Obel N, Lebech AM.

BMC Infect Dis. 2012 Nov 12;12:293. doi: 10.1186/1471-2334-12-293.

7.

Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz.

Carten ML, Kiser JJ, Kwara A, Mawhinney S, Cu-Uvin S.

Infect Dis Obstet Gynecol. 2012;2012:137192. doi: 10.1155/2012/137192. Epub 2012 Feb 28.

8.

Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.

Ouattara EN, Anglaret X, Wong AY, Chu J, Hsu HE, Danel C, Eholié S, Moh R, Gabillard D, Walensky RP, Freedberg KA.

AIDS. 2012 Mar 13;26(5):625-34. doi: 10.1097/QAD.0b013e328350fbfb.

9.

Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

Zorrilla CD, Tamayo-Agrait V.

HIV AIDS (Auckl). 2009;1:41-53. Epub 2009 Dec 8.

10.

Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.

Cressey TR, Stek A, Capparelli E, Bowonwatanuwong C, Prommas S, Sirivatanapa P, Yuthavisuthi P, Neungton C, Huo Y, Smith E, Best BM, Mirochnick M; IMPAACT P1026s Team.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):245-52. doi: 10.1097/QAI.0b013e31823ff052.

11.

Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception.

Huntington SE, Bansi LK, Thorne C, Anderson J, Newell ML, Taylor GP, Pillay D, Hill T, Tookey PA, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study and the National Study of HIV in Pregnancy and Childhood (NSHPC).

AIDS. 2011 Aug 24;25(13):1647-55. doi: 10.1097/QAD.0b013e32834982af.

13.

Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire.

Ekouevi DK, Coffie PA, Ouattara E, Moh R, Amani-Bosse C, Messou E, Sissoko M, Anglaret X, Eholié SP, Danel C, Dabis F; International Epidemiological Database to Evaluate AIDS West Africa; ANRS 1269 and ANRS 12136 Study Groups in Abidjan.

J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):183-7. doi: 10.1097/QAI.0b013e3181ff04e6.

14.

The treatment of patients with HIV.

Vogel M, Schwarze-Zander C, Wasmuth JC, Spengler U, Sauerbruch T, Rockstroh JK.

Dtsch Arztebl Int. 2010 Jul;107(28-29):507-15; quiz 516. doi: 10.3238/arztebl.2010.0507. Epub 2010 Jul 12. Review.

15.

Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA.

Hsu HE, Rydzak CE, Cotich KL, Wang B, Sax PE, Losina E, Freedberg KA, Goldie SJ, Lu Z, Walensky RP; CEPAC Investigators.

HIV Med. 2011 Feb;12(2):97-108. doi: 10.1111/j.1468-1293.2010.00856.x.

16.

Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C.

Brogly SB, Abzug MJ, Watts DH, Cunningham CK, Williams PL, Oleske J, Conway D, Sperling RS, Spiegel H, Van Dyke RB.

Pediatr Infect Dis J. 2010 Aug;29(8):721-7. doi: 10.1097/INF.0b013e3181e74a2f.

17.

Evaluation and treatment of the human immunodeficiency virus-1-exposed infant.

[No authors listed]

Paediatr Child Health. 2004 Jul;9(6):409-28. English, French.

18.

Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.

Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, Maartens G.

AIDS. 2008 Oct 18;22(16):2117-25. doi: 10.1097/QAD.0b013e328310407e.

19.

Efavirenz use during pregnancy and for women of child-bearing potential.

Chersich MF, Urban MF, Venter FW, Wessels T, Krause A, Gray GE, Luchters S, Viljoen DL.

AIDS Res Ther. 2006 Apr 7;3:11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk